CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic LeukemiaOfrat Beyar‐Katz, Yair Herishanu, Massimo Gentile et al.|Blood|2024Cited by 4
Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell TherapyNicolas Gazeau, Jordan Gauthier, Pere Barba et al.|Transplantation and Cellular Therapy|2022Cited by 0
Feasibility, Safety and Efficacy of Early Redosing with CD19-Targeted CAR-T Cells in Patients with Relapsed/Refractory Non-Hodgkin LymphomaValentin Ortiz-Maldonado, Jordan Gauthier, Jennifer J. Huang et al.|Transplantation and Cellular Therapy|2025Cited by 0
Phase 2 Trial of SC Versus IV Anakinra to Prevent CRS and Neurotoxicity in LBCL Patients Receiving Lisocabtagene Maraleucel: Final Analysis and Comparison to Historical ControlEmily C. Liang, Jordan Gauthier, Jennifer J. Huang et al.|Transplantation and Cellular Therapy|2025Cited by 0